<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7509">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918866</url>
  </required_header>
  <id_info>
    <org_study_id>DMP 115-416</org_study_id>
    <nct_id>NCT00918866</nct_id>
  </id_info>
  <brief_title>A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure</brief_title>
  <official_title>A Phase IV, Open-Label Safety Evaluation of the Effect of DEFINITY® on Pulmonary Artery Hemodynamics in Patients With Normal and Increased Pulmonary Artery Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lantheus Medical Imaging</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lantheus Medical Imaging</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse
      effects during Right Heart Catheterization. This research was requested by the FDA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IV safety study will provide safety data on potential systemic and pulmonary
      hemodynamic effects caused by the administration of DEFINITY® in patients who are to undergo
      right heart cardiac catheterization for clinical reasons. Using a right heart catheter for
      direct measurements of pulmonary artery hemodynamics will allow accurate assessments of
      potential alterations of the pulmonary vasculature. This will be further investigated by the
      inclusion of two patient populations, one with a baseline pulmonary artery pressure &lt; 35
      mmHg, and one with elevated baseline pulmonary artery pressure. The addition of immune
      parameter measurements will assess a potential link between systemic and pulmonary
      alterations and potential immune reactions following DEFINITY® administration.

      The inclusion of patients in this study is not based on a required echocardiogram with
      DEFINITY® administration because patients would be exposed to an unjustifiable risk of
      invasive right heart catheterization and are unlikely to consent to such a procedure.
      Therefore, patients undergoing heart catheterization for clinical reasons, or patients who
      are undergoing pulmonary artery hemodynamic assessments will be enrolled and receive
      DEFINITY® in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose</measure>
    <time_frame>31-35 minutes minus baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunology Panel- Complement 3A (C3A)</measure>
    <time_frame>Out to 70 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology Panel- Complement 5A(C5A)</measure>
    <time_frame>Out to 70 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology Panel- Interleuken-6</measure>
    <time_frame>Out to 70 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunology Panel- Tryptase</measure>
    <time_frame>Out to 70 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pulmonary Heart Disease</condition>
  <arm_group>
    <arm_group_label>Low Pulmonary Arterial Pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elevated Pulmonary Arterial Pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Definity</intervention_name>
    <description>one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight</description>
    <arm_group_label>Low Pulmonary Arterial Pressure</arm_group_label>
    <arm_group_label>Elevated Pulmonary Arterial Pressure</arm_group_label>
    <other_name>Perflutren Lipid Microsphere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Appropriate candidate scheduled to undergo right heart catheterization and
             measurement of pulmonary artery hemodynamics for clinical reasons

          -  Be male or female above the age of 18

          -  Female patients who no longer have child-bearing potential

          -  Women of Child-Bearing Potential(WOCBP) who:

               1. are not pregnant and have been using an adequate and medically approved method
                  of contraception

               2. have a negative urine pregnancy test

          -  Be able and willing to communicate effectively with study center personnel.

        Exclusion Criteria:

          -  Women who are pregnant or lactating

          -  Known hypersensitivity or contraindication to or greater heart block

          -  Previous heart transplant

          -  Known right-to-left shunt (including atrial septal defect)

          -  Severe pulmonary artery hypertension (i.e., &gt; 75 mmHg

          -  Current uncontrolled ventricular tachycardia

          -  Second-degree or greater heart block

          -  Any contraindications for the use of a right heart catheter
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lantheus Medical Imaging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>St. Louis Park</city>
        <state>Minnesota</state>
        <zip>55426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Consultants</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Hospital</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch at Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>March 30, 2015</lastchanged_date>
  <firstreceived_date>June 4, 2009</firstreceived_date>
  <firstreceived_results_date>December 17, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 4</keyword>
  <keyword>DEFINITY®</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>pulmonary artery pressure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pulmonary Heart Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Definity</mesh_term>
    <mesh_term>Perflutren</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>participants were recruited from hospitals and clinics in the USA between July 2009 and December 2009</recruitment_details>
      <pre_assignment_details>There were no randomization procedures or other pre-assignment requirements in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Low Pulmonary Arterial Pressure</title>
          <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
        </group>
        <group group_id="P2">
          <title>Elevated Pulmonary Arterial Pressure</title>
          <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Low Pulmonary Arterial Pressure</title>
          <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
        </group>
        <group group_id="B2">
          <title>Elevated Pulmonary Arterial Pressure</title>
          <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="16"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.9" spread="10.8"/>
                <measurement group_id="B2" value="57.4" spread="15.1"/>
                <measurement group_id="B3" value="57.2" spread="12.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="7"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Pulmonary artery pressure 1 minute pre-dose</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30.4" spread="3.38"/>
                <measurement group_id="B2" value="50.9" spread="10.31"/>
                <measurement group_id="B3" value="40.7" spread="12.89"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose</title>
        <description>Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose</description>
        <time_frame>31-35 minutes minus baseline</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Per the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Low Pulmonary Arterial Pressure</title>
            <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
          </group>
          <group group_id="O2">
            <title>Elevated Pulmonary Arterial Pressure</title>
            <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="16"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose</title>
            <description>Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose</description>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.9" spread="18.03"/>
                  <measurement group_id="O2" value="-1.7" spread="10.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunology Panel- Complement 3A (C3A)</title>
        <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
        <time_frame>Out to 70 minutes</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Low Pulmonary Arterial Pressure</title>
            <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
          </group>
          <group group_id="O2">
            <title>Elevated Pulmonary Arterial Pressure</title>
            <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunology Panel- Complement 3A (C3A)</title>
            <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-45.80" spread="338.14"/>
                  <measurement group_id="O2" value="-38.20" spread="414.86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunology Panel- Complement 5A(C5A)</title>
        <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
        <time_frame>Out to 70 minutes</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Low Pulmonary Arterial Pressure</title>
            <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
          </group>
          <group group_id="O2">
            <title>Elevated Pulmonary Arterial Pressure</title>
            <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunology Panel- Complement 5A(C5A)</title>
            <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
            <units>ng/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.95" spread="3.56"/>
                  <measurement group_id="O2" value="0.78" spread="4.55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunology Panel- Interleuken-6</title>
        <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
        <time_frame>Out to 70 minutes</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Low Pulmonary Arterial Pressure</title>
            <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
          </group>
          <group group_id="O2">
            <title>Elevated Pulmonary Arterial Pressure</title>
            <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunology Panel- Interleuken-6</title>
            <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
            <units>pg/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.31" spread="1.46"/>
                  <measurement group_id="O2" value="0.15" spread="2.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunology Panel- Tryptase</title>
        <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
        <time_frame>Out to 70 minutes</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Low Pulmonary Arterial Pressure</title>
            <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
          </group>
          <group group_id="O2">
            <title>Elevated Pulmonary Arterial Pressure</title>
            <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="14"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Immunology Panel- Tryptase</title>
            <description>Evaluate the Immunology Panel after the administration of DEFINITY</description>
            <units>ug/ml</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.24" spread="0.82"/>
                  <measurement group_id="O2" value="-0.01" spread="1.46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 32 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low Pulmonary Arterial Pressure</title>
          <description>Subjects with pulmonary arterial pressure (PAP) of &lt; or = to 35 mmHg.</description>
        </group>
        <group group_id="E2">
          <title>Elevated Pulmonary Arterial Pressure</title>
          <description>Subjects with a PAP of &gt; or = to 35 mmHg.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dana Washburn, M.D.</name_or_title>
      <organization>Lantheus Medical Imaging</organization>
      <phone>978-671-8686</phone>
      <email>dana.washburn@lantheus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
